Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 11;20(1):1693.
doi: 10.1186/s12889-020-09835-7.

Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 global burden of disease study

Hairong He  1   2 , Hongjun Xie  3 , Yule Chen  3 , Chengzhuo Li  2 , Didi Han  2 , Fengshuo Xu  2 , Jun Lyu  4   5   6
Affiliations

Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 global burden of disease study

Hairong He et al. BMC Public Health. .

Abstract

Background: The aim of this study is to describe the prevalence and mortality of bladder cancer (BCa) using data obtained in the Global Burden of Disease study performed in 2017 (GBD 2017).

Methods: Data on BCa for 2017, including prevalence, mortality, and disability-adjusted life years (DALYs), were obtained from GBD 2017 at the global, regional, and national levels. We also analyzed the association of BCa burden with the country development level.

Results: There were 2.63 million BCa cases estimated from the GBD 2017 data, with 200,000 persons dying of BCa, resulting in 3.60 million DALYs in 2017. The age-standardized prevalence (ASP) of BCa was 32.91/100,000 persons, and age-standardized death rate (ASDR) was 2.57/100,000 persons. The ASP and ASDR of BCa were higher in males than in females, and higher in people older than 60 years. The ASP and ASDR of BCa were higher in Western Europe and Central Europe than in South Asia, Andean Latin America, and Central Latin America, and higher in countries with a higher sociodemographic index (SDI). Correlation analysis identified that the ASP and ASDR of BCa were positively correlated with the country SDI (P < 0.0001 and ρ = 0.68 for ASP, and P = 0.0048 and ρ = 0.20 for ASDR). In addition, 33.72% deaths and 36.80% DALYs caused by BCa could be attributed to smoking globally.

Conclusion: The prevalence and mortality of BCa were very high in 2017, especially in high-SDI countries. Smoking-cessation strategies should be strengthened to control the burden associated with BCa.

Keywords: Bladder cancer; GBD 2017; Mortality; Prevalence.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Contribution of different age group for male and female to absolute bladder cancer prevalent cases (a), death number (b), and DALYs number (c) globally in 2017. DALYs,disability-adjusted life years
Fig. 2
Fig. 2
Age-standardised prevalence (a), mortality (b) and DALYs (c) rates of bladder cancer in 2017, by age and sex. DALYs, disability-adjusted life years
Fig. 3
Fig. 3
Age-standardised prevalence (a), mortality (b) and DALYs (c) rates of bladder cancer in 195 countries or territories in 2017. DALYs, disability-adjusted life years. The figure is our own and is drawn using R software (version 3.5.1; https://www.r-project.org/) by loading the “maps” and “ggplots2” packages
Fig. 4
Fig. 4
The correlation between age-standardised prevalence (a), mortality (b) and DALYs (c) rates of bladder cancer and SDI of 195 countries or territories in 2017. The fitted curve and 95% CI are obtained by locally weighted regression. DALYs,disability-adjusted life years
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Netto GJ, Tafe LJ. Emerging bladder Cancer biomarkers and targets of therapy. Urol Clin North Am. 2016;43(1):63–76. doi: 10.1016/j.ucl.2015.08.006. - DOI - PubMed
    1. Cumberbatch K, He T, Thorogood Z, Gartrell BA. Emerging drugs for urothelial (bladder) cancer. Expert Opin Emerg Drugs. 2017;22(2):149–164. doi: 10.1080/14728214.2017.1336536. - DOI - PubMed
    1. Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Emerging therapeutic targets in bladder cancer. Cancer Treat Rev. 2015;41(2):170–178. doi: 10.1016/j.ctrv.2014.11.003. - DOI - PubMed
    1. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–866. doi: 10.1056/NEJMoa022148. - DOI - PubMed